Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab versus placebo plus standard of care in active lupus nephritis (Phase III, Slovakia)
2019-003211-57Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lupus nephritis (LN) comparing Secukinumab 300 mg + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Complete Renal Response at primary time point. Started Jan 2020; status: terminated.
02
Drugs
secukinumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on 2019-003211-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003211-57.